BlackRock Investment Management’s Capricor Therapeutics CAPR Stock Holding History

BlackRock Investment Management’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1K	Hold	41	–	–	﹤0.01%	3903
2016 Q3	$1K	Hold	41	–	–	﹤0.01%	3909
2016 Q2	$2K	Hold	41	–	–	﹤0.01%	3972
2016 Q1	$1K	Hold	41	–	–	﹤0.01%	4012
2015 Q4	$1K	Hold	41	–	–	﹤0.01%	4051
2015 Q3	$2K	Hold	41	–	–	﹤0.01%	4071
2015 Q2	$2K	Buy	+41	New	+$2.57K	﹤0.01%	4068

Other funds holding CAPR

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Investment Management's CAPR Position: Q4 2016 in Review

BlackRock Investment Management held its Capricor Therapeutics (CAPR) position steady in Q4 2016 at 41 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #3903.

BlackRock Investment Management first reported a position in CAPR in Q2 2015 and has held it in 7 quarters since. The position peaked at $2K in Q2 2016. 20 funds tracked by Wall St. Rank hold CAPR as of Q4 2016.

BlackRock Investment Management held 41 shares of Capricor Therapeutics worth $1K as of Q4 2016.
BlackRock Investment Management left its Capricor Therapeutics share count unchanged in Q4 2016.
Capricor Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3903 holding.
BlackRock Investment Management first reported a position in Capricor Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Investment Management's Capricor Therapeutics position peaked at $2K in Q2 2016.
20 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.